COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 3391.T

Comparison against 3391.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

118.64

Increased from previous period

OCF/share 50–75% of 3391.T's 186.00. Martin Whitman would question if overhead or strategy constrains cash flow.

Free Cash Flow per Share

118.64

Increased from previous period

FCF/share 50–75% of 3391.T's 186.00. Martin Whitman would wonder if there's a cost or pricing disadvantage.

Capex-to-Operating Cash Flow

No Data

No Data available this quarter, please select a different quarter.

Income Quality Ratio (OCF / Net Income)

1.25

Decreased from previous period

Below 0.5x 3391.T's 2.55. Michael Burry would expect an eventual correction in reported profits.

Operating Cash Flow-to-Sales Ratio

4.24%

Decreased from previous period

1.25–1.5x 3391.T's 3.79%. Bruce Berkowitz would see if the competitor lacks the same operational or margin advantages.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 3391.T

Comparison against 3391.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

118.64

Increased from previous period

OCF/share 50–75% of 3391.T's 186.00. Martin Whitman would question if overhead or strategy constrains cash flow.

Free Cash Flow per Share

118.64

Increased from previous period

FCF/share 50–75% of 3391.T's 186.00. Martin Whitman would wonder if there's a cost or pricing disadvantage.

Capex-to-Operating Cash Flow

No Data

No Data available this quarter, please select a different quarter.

Income Quality Ratio (OCF / Net Income)

1.25

Decreased from previous period

Below 0.5x 3391.T's 2.55. Michael Burry would expect an eventual correction in reported profits.

Operating Cash Flow-to-Sales Ratio

4.24%

Decreased from previous period

1.25–1.5x 3391.T's 3.79%. Bruce Berkowitz would see if the competitor lacks the same operational or margin advantages.

Select Chart Metric: